Results 261 to 270 of about 214,982 (356)

From In Vitro Efficacy to Long‐Term HbA1c Response for GLP‐1R/GlucagonR Agonism Using the 4GI‐HbA1c Systems Model

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
A combined systems model (4GI‐HbA1c) was developed to predict glucose and HbA1c responses to GLP‐1 and GLP‐1/glucagon receptor agonists using early pharmacokinetic and in vitro efficacy data. Validated with short‐term CGM data, the model accurately predicted 26‐week clinical outcomes for liraglutide and cotadutide, demonstrating its value in supporting
Rolien Bosch, Marcella Petrone, Rosalin Arends, Eric J. G. Sijbrands, Sven Hoefman, Nelleke Snelder   +5 more
wiley   +1 more source

RNA editing deficiency models differential immunogenicity of pancreatic α- and β-cells. [PDF]

Mol Metab
Peleg S, Zamashanski L, Belin J, Novoselsky R, Cohen-Fultheim R, Knebel UE, Glaser B, Itzkovitz S, Kaestner KH, Powers AC, Levanon EY, Klochendler A, Dor Y.   +12 more
europepmc   +1 more source

Hepatotrophic effect of insulin [PDF]

, 1987
Francavilla, A, Starzl, TE
core  

Influence of glucagon on pancreatic exocrine secretion.

, 1969
Walter P. Dyck, J Rudick, Barton Hoexter, Henry D. Janowitz   +3 more
openalex  

A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Dulaglutide, a long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist, is approved for improving glycemic control and reducing cardiovascular risks in patients with type 2 diabetes mellitus (T2DM). This research investigates the effect of dulaglutide on gastric emptying and its impact on the pharmacokinetics (PK) of orally administered ...
Maria M. Posada, Karen B. Schneck, Bridget L. Morse, Luc R. A. Rougee, Lai San Tham, Jessica F. Rehmel, Brian Thompson, Stephen D. Stamatis, Stephen D. Hall, Gemma L. Dickinson   +9 more
wiley   +1 more source

The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.

Health Technol Assess
Nunns M, Febrey S, Buckland J, Abbott R, Whear R, Bethel A, Boddy K, Shaw L, Coon JT, Melendez-Torres GJ.   +9 more
europepmc   +1 more source

Obesity and the Gut-Brain Axis in Type 1 Diabetes Mellitus: Terra Incognita? [PDF]

Curr Obes Rep
Argyrakopoulou G, Gitsi E, Dalamaga M, Kokkinos A.   +3 more
europepmc   +1 more source

The Impact of Okra (Abelmoschus esculentus) Supplementation on Diabetes and Obesity Biomarkers in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Phytotherapy Research, EarlyView.
ABSTRACT Conflicting results have been reported regarding the effects of okra on diabetes biomarkers in patients with type 2 diabetes. These inconsistencies may stem from factors such as dosage, intervention duration, and study design. To address these discrepancies, this systematic review and meta‐analysis of randomized controlled trials (RCTs) was ...
Ying Fan, Lei Wu, Yalan Zhang, Qin Hu, Jing Mei, Kousalya Prabahar, Benjamin Hernández‐Wolters, Hamed Kord‐Varkaneh, Changjiang Lei, Su Zheng   +9 more
wiley   +1 more source

GLP-1R in diabetes mellitus: from basic discovery to therapeutics development. [PDF]

Front Pharmacol
Li S, Huang N, Wang M, Huang W, Luo Y, Huang J.   +5 more
europepmc   +1 more source

Astrocyte Lipid Droplet Dynamics Orchestrate Neurological Disorders and Therapeutic Horizons

Small Science, EarlyView.
This review examines astrocyte lipid droplet (LD) metabolism in neurological disorders, including Alzheimer's disease, stroke, epilepsy, and glioma. It analyzes regulatory mechanisms governing LD formation, transport, and degradation in astrocytes, highlighting their potential as biomarkers and therapeutic targets through integrative multiomics ...
Jiani Zhong, Yanyi Peng, Lingyue Zhang, Bo Xiao, Mengqi Zhang   +4 more
wiley   +1 more source